Caris Life Sciences Inc(CAI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 3 at 7:57 PM ET (Korea 11/4 09:57)
Full metrics table
| Index | - | P/E | 88.24 | EPS (ttm) | 0.37 | Insider Own | 55.29% | Shs Outstand | 282.6M | Perf Week | -2.44% |
| Market Cap | 9.28B | Forward P/E | 93.66 | EPS next Y | 191.34% | Insider Trans | -0.58% | Shs Float | 126.3M | Perf Month | 8.09% |
| Enterprise Value | 8.94B | PEG | - | EPS next Q | 0.03 | Inst Own | 50.68% | Short Float | 10.76% | Perf Quarter | 99.7% |
| Income | 0.11B | P/S | 9.38 | EPS this Y | 129.56% | Inst Trans | -1.64% | Short Ratio | 2.82 | Perf Half Y | 73.35% |
| Sales | 0.99B | P/B | 15.69 | EPS next 5Y | - | ROA | 9.62% | Short Interest | 13.59M | Perf YTD | 21.76% |
| Book/sh | 2.09 | P/C | 11.7 | EPS past 3/5Y | -7.57% - | ROE | 20.13% | 52W High | -10% ($36.50) | Perf Year | 9.72% |
| Cash/sh | 2.81 | P/FCF | 79.86 | Sales past 3/5Y | 62.87% - | ROIC | 10.13% | 52W Low | 131.5% ($14.19) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | 51.39 | EPS Y/Y TTM | 113.1% | Gross Margin | 69.66% | Volatility(W/M) | 6.81% 6.98% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 9.04 | Sales Y/Y TTM | 85.37% | Oper. Margin | 15.49% | ATR (14) | 1.96 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.88 | EPS Q/Q | 99.88% | Profit Margin | 10.62% | RSI (14) | 55.61 | Recom | 1.64 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.53 | Sales Q/Q | 45.38% | SMA20 | 4.13% ($31.55) | Beta | 0.79 | Target Price | $32.46 |
| Payout | - | Debt/Eq | 0.76 | Earnings | 2026/11/4 | SMA50 | 11.69% ($29.41) | Rel Volume | 0.55 | Prev Close | $32.1 |
| Employees | 1846 | LT Debt/Eq | 0.75 | EPS/Sales Surpr. | -100% 10.75% | SMA200 | 51.87% ($21.63) | Avg Volume(3M) | 4.83M | Price | $32.85 |
| IPO | 2025/6/18 | Option/Short | Yes/Yes | Trades | 23530 | Volume | 2,675,951 | Change | 2.34% |
🧬 An AI-powered diagnostics company specializing in cancer molecular diagnostics and precision medicine. It supports personalized treatment for cancer patients through whole-genome and whole-transcriptome sequencing that analyzes tumor tissue and blood, and is rapidly growing in the field of precision oncology based on its extensive molecular database. Its core business is molecular profiling services.
Over the past 1 year, on the higher side
10% below its 1-year high.
Traded less than usual. That is 55% of its average volume.
Next earnings report: November 4
That is today.
CAI makes money exceptionally well
Of every $100 in sales, $15.49 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +129.6% this year.
Tap to view numbers
However, it looks expensive
For a company earning $100 a year, you would pay $8,824. Peers typically go for $1,236.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 50.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #25 of 597 in the industry
Based on market cap of $9B.
TGTX#24 TG Therapeutics Inc $9B PER 22.1 CAI#25 Caris Life Sciences Inc $9B PER 88.2 
TWST#26 Twist Bioscience Corp $9B PER - 
SYRE#27 Spyre Therapeutics Inc $9B PER - 
MDGL#28 Madrigal Pharmaceuticals Inc $9B PER - 
FAQ
What kind of company is CAI?
CAI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CAI?
The market cap of CAI is approximately $9.3B, ranking 964 within its sector.
What is the P/E ratio of CAI?
CAI has a P/E ratio of approximately 88.2x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for CAI?
CAI has recorded a 52-week high of $36.50 and a low of $14.19.
